To 10X & Beyond, AgentV™-DSP Arrives Ready To Rock

Extracellular vesicle manufacturing has faced a persistent challenge: downstream processing methods that sacrifice yield for purity, with recovery rates plummeting below 5% through standard filtration steps. Filter fouling during clarification, tangential flow filtration, and guard filtration creates costly bottlenecks that make clinical-scale production economically prohibitive. AgentV-DSP addresses this constraint through a simple one-milliliter-per-liter media additive containing recombinant biological molecules that prevent filter fouling and increase loading capacity.

The result represents a quantum efficiency shift: EV yields improve up to tenfold compared to standard protocols, achieving approximately 50% recovery versus 5% without treatment. Learn how this breakthrough, combined with optimized upstream processes, reduces per-dose costs from $2,000 to under $250 while cutting GMP suite time from 120 days to 15 days for equivalent clinical-scale output.